Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Patients with higher PTH tended to be younger; have higher body weight, fewer comorbid conditions, and higher serum phosphorus levels; and be more often prescribed sevelamer, intravenous active vitamin D, and cinacalcet (Table 1 ).

Source: Patient characteristics. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Participants were recruited through 792 unique facilities from North America (the United States and Canada), Japan, Europe (Belgium, France, Germany, Italy, Spain, Sweden, and the United Kingdom), Australia, New Zealand, Russia, the Gulf Cooperation Council (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and United Arab Emirates), Turkey, and China.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Secondary hyperparathyroidism, weight loss, and longer term mortality in haemodialysis patients: results from the DOPPS

Study design awaiting verification · Journal of Cachexia, Sarcopenia and Muscle · 2021

Original publication title

Secondary hyperparathyroidism, weight loss, and longer term mortality in haemodialysis patients: results from the DOPPS

Hirotaka Komaba; Junhui Zhao; Suguru Yamamoto; Takanobu Nomura; Douglas S. Fuller; Keith P. McCullough; Pieter Evenepoel; Anders Christensson; Xinju Zhao; Mona Alrukhaimi; Fadwa Al‐Ali; Eric W. Young; Bruce M. Robinson; Masafumi Fukagawa

© 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Secondary hyperparathyroidism may be a novel mechanism of wasting, corroborating experimental data, and, among chronic dialysis patients, this pathway may be a mediator between elevated PTH levels and mortality. Future research should determine whether PTH‐lowering therapy can limit weight loss and improve longer term dialysis outcomes.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Wasting is a common complication of kidney failure that leads to weight loss and poor outcomes. Recent experimental data identified parathyroid hormone (PTH) as a driver of adipose tissue browning and wasting, but little is known about the relations among secondary hyperparathyroidism, weight loss, and risk of mortality in dialysis patients.

Source: Background

Abstract: What methods does the paper describe?

We included 42,319 chronic in‐centre haemodialysis patients from the Dialysis Outcomes and Practice Patterns Study phases 2 to 6 (2002 to 2018). Linear mixed models were used to estimate the association between baseline PTH and percent weight change over 12 months, adjusting for country, demographics, comorbidities, and labs. Accelerated failure time models were used to assess 12 month weight loss as a mediator between baseline high PTH and mortality after 12 months.

Source: Methods

Abstract: Results

Baseline PTH was inversely associated with 12 month weight change: 12 month weight loss >5% was observed in 21%, 18%, 18%, 17%, 15%, and 14% of patients for PTH ≥600 pg/mL, 450 to 600, 300 to 450, 150 to 300, 50 to 150, and <50 pg/mL, respectively. In adjusted analyses, 12 month weight change compared with PTH 150 to 299 pg/mL was −0.60%, −0.12%, −0.10%, +0.15%, and +0.35% for PTH ≥600, 450 to 600, 300 to 450, 50 to 150, and <50 pg/mL, respectively. This relationship was robust regardless of recent hospitalization and was more pronounced in persons with preserved appetite.

During follow‐up after the 12 month weight measure [median, 1.0 (interquartile range, 0.6 to 1.7) years; 6125 deaths], patients with baseline PTH ≥600 pg/mL had 11% [95% confidence interval (CI), 9 to 13%] shorter lifespan, and 18% (95% CI, 14 to 23%) of this effect was mediated through weight loss ≥2.5%.

Source: Results

Abstract: Conclusions

Secondary hyperparathyroidism may be a novel mechanism of wasting, corroborating experimental data, and, among chronic dialysis patients, this pathway may be a mediator between elevated PTH levels and mortality. Future research should determine whether PTH‐lowering therapy can limit weight loss and improve longer term dialysis outcomes.

Source: Conclusions
Authors’ abstract

Abstract

Background

Wasting is a common complication of kidney failure that leads to weight loss and poor outcomes. Recent experimental data identified parathyroid hormone (PTH) as a driver of adipose tissue browning and wasting, but little is known about the relations among secondary hyperparathyroidism, weight loss, and risk of mortality in dialysis patients.

Methods

We included 42,319 chronic in‐centre haemodialysis patients from the Dialysis Outcomes and Practice Patterns Study phases 2 to 6 (2002 to 2018). Linear mixed models were used to estimate the association between baseline PTH and percent weight change over 12 months, adjusting for country, demographics, comorbidities, and labs. Accelerated failure time models were used to assess 12 month weight loss as a mediator between baseline high PTH and mortality after 12 months.

Results

Baseline PTH was inversely associated with 12 month weight change: 12 month weight loss >5% was observed in 21%, 18%, 18%, 17%, 15%, and 14% of patients for PTH ≥600 pg/mL, 450 to 600, 300 to 450, 150 to 300, 50 to 150, and <50 pg/mL, respectively. In adjusted analyses, 12 month weight change compared with PTH 150 to 299 pg/mL was −0.60%, −0.12%, −0.10%, +0.15%, and +0.35% for PTH ≥600, 450 to 600, 300 to 450, 50 to 150, and <50 pg/mL, respectively. This relationship was robust regardless of recent hospitalization and was more pronounced in persons with preserved appetite.

During follow‐up after the 12 month weight measure [median, 1.0 (interquartile range, 0.6 to 1.7) years; 6125 deaths], patients with baseline PTH ≥600 pg/mL had 11% [95% confidence interval (CI), 9 to 13%] shorter lifespan, and 18% (95% CI, 14 to 23%) of this effect was mediated through weight loss ≥2.5%.

Conclusions

Secondary hyperparathyroidism may be a novel mechanism of wasting, corroborating experimental data, and, among chronic dialysis patients, this pathway may be a mediator between elevated PTH levels and mortality. Future research should determine whether PTH‐lowering therapy can limit weight loss and improve longer term dialysis outcomes.

Publication and source details

Original title: Secondary hyperparathyroidism, weight loss, and longer term mortality in haemodialysis patients: results from the DOPPS

Hirotaka Komaba; Junhui Zhao; Suguru Yamamoto; Takanobu Nomura; Douglas S. Fuller; Keith P. McCullough; Pieter Evenepoel; Anders Christensson; Xinju Zhao; Mona Alrukhaimi; Fadwa Al‐Ali; Eric W. Young; Bruce M. Robinson; Masafumi Fukagawa

Journal of Cachexia, Sarcopenia and Muscle · 2021

* Correspondence to: Hirotaka Komaba, Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, 143 Shimo‐Kasuya, Isehara 259‐1193, Japan. Phone: +81‐463‐93‐1121 ext 2351, Email: hkomaba@tokai-u.jp © 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T12:32:14.049780+00:00

DOI: 10.1002/jcsm.12722 · PMC8350219